Glaukos Corporation GKOS R2K

Q: What is the current share price of Glaukos Corporation (GKOS)?

As of 2026-07-14 21:23 PDT, Glaukos Corporation (GKOS) trades at $152.45 on NYSE. Its 52-week range is $74.67 to $155.07.

Q: What is the market capitalisation of GKOS?

Glaukos Corporation (GKOS) has a market capitalisation of $8.95B on NYSE.

Q: What is the P/E ratio of GKOS?

GKOS trades at a trailing price-to-earnings (P/E) ratio of -46.20. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 11.03.

Q: What is the return on equity (ROE) of GKOS?

GKOS has a return on equity (ROE) of -26.39%. Its return on capital employed (ROCE) is -25.20%.

Q: Is GKOS a good stock to buy?

This page provides a data-driven analysis of Glaukos Corporation (GKOS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.glaukos.com

Company Profile ↓

$152.45

+46.32% 1Y

Mkt Cap$8.95B

P/E-46.20

P/B11.03

52W High$155.07

52W Low$74.67

Book Value$11.50

EPS (TTM)$-3.30

Company Overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 33.6% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.16.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $507.44M (+32.3% YoY); net profit $-187.69M.
Trailing 12 Months Year-on-year growth — revenue +41.2%.
5-Year Trend Long-term compounding — revenue CAGR 33.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	33.61%
1 Year:	41.20%

Stock Price Performance

1 Year:	+46.32%
6 Months:	+35.01%
3 Months:	+27.58%
1 Month:	+22.69%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 97% of range

$74.67 $155.07

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)67.31 · Neutral

Price Performance

1M+22.69%

3M+27.58%

6M+35.01%

1Y+46.32%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 33.6% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-46.20

Industry PE

25.41

Forward P/E

343.64

PEG Ratio

Book Value

$11.50

Price to Book

11.03

P/S

13.51

EV/EBITDA

-164.38

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

33.61%

Profit 5Y

Revenue (YoY)

41.20%

Earnings (YoY)

Profitability & Returns

ROCE

-25.20%

ROE

-26.39%

ROA

-5.78%

Profit Margin

-34.34%

Op Margin

-13.19%

Gross Margin

78.08%

EPS (Latest Qtr)

$-0.34

EPS (TTM)

$-3.30

Balance Sheet & Liquidity

Debt/Equity

0.16

Quick Ratio

4.43

Current Ratio

5.43

Debt

$105.87M

Total Assets

$893.33M

Current Assets

$485.75M

Working Capital

$373.71M

Ownership

Promoter Holding

3.62%

Chg in Prom Hold

-0.01%

FII / Inst Holding

102.30%

Chg in FII Hold

-2.12%

Financial Snapshot

Enterprise Value

$8.95B

Total Revenue (TTM)

$551.35M

EBITDA

$-44.25M

Free Cash Flow

$6.09M

Operating Cash Flow

$-8.79M

Shares Outstanding

58.73M

Gross Margin

78.08%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GKOS Glaukos Corporation R2K	152.45	-46.20	$8.95B	0.00%	-25.20%	-26.39%	33.61%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	35.91M	41.28M	40.41M	41.65M	40.13M	43.16M	43.91M	54.08M	54.03M	58.60M	58.51M	65.85M	55.34M	31.56M	64.83M	73.23M	67.97M	78.09M	74.71M	73.24M	67.68M	72.69M	71.27M	71.23M	73.90M	80.40M	78.05M	85.62M	95.69M	96.67M	-	106.66M	124.12M	133.54M	143.12M	150.57M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.32M	26.90M	28.83M	144.64M	33.34M
Gross Profit	19.97M	24.20M	25.69M	28.36M	30.73M	35.76M	34.69M	37.02M	34.35M	37.00M	37.90M	46.96M	46.91M	50.73M	50.81M	49.95M	22.81M	9.89M	46.90M	53.64M	51.34M	60.33M	59.34M	56.38M	50.62M	54.85M	54.41M	54.01M	55.83M	60.30M	59.54M	65.36M	73.14M	74.09M	-	82.35M	97.22M	104.71M	-1.52M	117.23M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	103.03M	119.91M	121.07M	138.35M	137.09M
Operating Income	621.00K	2.12M	1.03M	468.00K	304.00K	-3.87M	748.00K	532.00K	-3.71M	-4.25M	-6.94M	1.90M	-1.94M	-6.24M	-12.41M	-29.70M	-52.61M	-47.20M	-12.35M	-11.39M	-11.80M	-14.22M	11.02M	-17.87M	9.79M	-36.76M	-21.61M	-33.73M	-32.99M	-29.07M	-28.01M	-39.07M	-29.97M	-24.66M	-	-20.68M	-22.69M	-16.36M	-139.87M	-19.86M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7.35M	-8.63M	-4.63M	-125.44M	-5.29M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.16M	1.15M	1.18M	1.15M	1.12M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17.82M	-19.41M	-16.00M	-139.82M	-19.30M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	326.00K	248.00K	234.00K	-6.16M	484.00K
Net Income	897.00K	2.33M	1.16M	134.00K	878.00K	-3.30M	1.32M	1.01M	-2.71M	-5.40M	-6.62M	1.78M	-1.34M	-6.31M	-13.51M	36.58M	-54.06M	-39.89M	-15.75M	-10.65M	-16.47M	-17.48M	6.23M	-21.87M	5.38M	-45.54M	-27.58M	-31.46M	-34.63M	-32.81M	-30.44M	-40.84M	-50.55M	-21.41M	-	-18.15M	-19.66M	-16.23M	-133.66M	-19.78M
Diluted EPS	0.03	0.06	0.03	0.00	0.02	-0.10	0.04	0.03	-0.08	-0.15	-0.19	0.04	-0.04	-0.17	-0.37	0.84	-1.24	-0.90	-0.35	-0.24	-0.36	-0.38	0.13	0.47	0.11	-0.96	-0.58	-0.66	-0.72	-0.68	-0.63	-0.82	-1.00	-0.39	-	-0.32	-0.34	-0.28	-2.32	-0.34
R&D Expense	7.06M	6.96M	7.81M	7.40M	8.94M	9.63M	9.80M	10.53M	10.91M	12.61M	13.20M	12.96M	13.93M	-	-	-	-	-	-	-	21.22M	-	-	-	26.88M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	20.95M	45.59M	71.70M	114.40M	159.25M	181.28M	236.98M	224.96M	-	282.86M	314.71M	383.48M	507.44M
Cost of Revenue	-	-	-	-	-	-	-	-	-	68.98M	75.58M	94.03M	224.68M
Gross Profit	18.41M	34.17M	58.71M	98.22M	138.20M	156.20M	198.40M	133.24M	-	213.88M	239.14M	289.45M	282.76M
Operating Expenses	-	-	-	-	-	-	-	-	-	316.20M	362.84M	397.59M	482.36M
Operating Income	-14.20M	-13.17M	-10.30M	4.24M	-2.28M	-13.00M	-50.29M	-123.55M	-	-102.31M	-123.70M	-108.14M	-199.60M
EBITDA	-	-	-	-	-	-	-	-	-	-48.76M	-82.12M	-95.64M	-146.06M
Interest Expense	-	-	-	-	-	-	-	-	-	13.72M	13.63M	10.04M	4.63M
Pretax Income	-	-	-	-	-	-	-	-	-	-98.43M	-133.73M	-145.60M	-193.04M
Tax Provision	-	-	-	-	-	-	-	-	-	766.00K	934.00K	771.00K	-5.35M
Net Income	-12.64M	-12.13M	-37.24M	4.52M	-92.00K	-12.95M	15.42M	-120.35M	-	-99.19M	-134.66M	-146.37M	-187.69M
Diluted EPS	-	-5.29	-2.13	0.12	0.00	-0.37	0.37	-2.70	-	-2.09	-2.78	-2.77	-3.28
R&D Expense	15.51M	19.20M	25.05M	29.22M	38.91M	49.68M	-	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	26.02M	116.66M	134.37M	165.84M	206.97M	818.40M	1.01B	-	1.00B	940.41M	974.76M	893.49M
Current Assets	-	-	-	-	-	-	-	-	-	-	443.86M	395.46M	449.79M	474.98M
Cash & Equivalents	1.73M	6.73M	2.30M	21.57M	6.49M	24.51M	29.82M	62.43M	96.60M	-	119.53M	93.47M	169.63M	90.81M
Inventory	-	-	-	-	-	-	-	-	-	-	37.84M	41.99M	57.68M	63.56M
Receivables	-	-	-	-	-	-	-	-	-	-	36.07M	39.85M	60.74M	108.61M
Total Liabilities	-	-	29.55M	21.47M	17.10M	27.63M	33.11M	145.13M	338.05M	-	472.38M	478.65M	207.82M	237.33M
Current Liabilities	-	-	20.19M	20.36M	16.94M	26.79M	30.36M	57.70M	49.70M	-	72.36M	74.01M	75.12M	101.28M
Long Term Debt	-	-	8.97M	765.00K	-	-	-	-	-	280.03M	281.40M	282.77M	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	382.48M	383.74M	103.40M	103.88M
Total Equity	-136.20M	-149.04M	-151.30M	95.19M	117.27M	138.20M	173.86M	673.27M	667.45M	-	530.00M	461.77M	766.93M	656.15M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	47.78M	49.15M	56.47M	57.54M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-2.19M	12.31M	26.09M	18.86M	-369.00K	-22.99M	-	-33.08M	-57.76M	-61.32M	-14.79M
Investing Cash Flow	-	-	-85.63M	-26.12M	-12.39M	-26.40M	43.43M	-205.06M	-	44.78M	14.10M	47.83M	-77.61M
Financing Cash Flow	-	-	107.11M	-1.64M	4.67M	21.58M	-9.64M	262.54M	-	6.25M	15.04M	91.54M	11.89M
Capital Expenditure	-852.00K	-868.00K	-877.00K	-6.28M	-6.31M	-10.31M	-4.72M	-6.93M	-	-30.27M	-20.25M	-6.30M	-24.27M
Free Cash Flow	-	-	-3.06M	6.03M	19.78M	8.55M	-5.09M	-29.92M	-	-63.35M	-78.01M	-67.62M	-39.06M
Net Change in Cash	-	-	-	-	-	-	-	-	-	17.95M	-28.62M	78.05M	-80.52M
Share Buybacks	132.00K	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	87.9%	75.0%	81.9%	85.9%	86.8%	86.2%	83.7%	59.2%	-	75.6%	76.0%	75.5%	55.7%
Operating Margin %	-67.8%	-28.9%	-14.4%	3.7%	-1.4%	-7.2%	-21.2%	-54.9%	-	-36.2%	-39.3%	-28.2%	-39.3%
Net Margin %	-60.3%	-26.6%	-51.9%	4.0%	-0.1%	-7.1%	6.5%	-53.5%	-	-35.1%	-42.8%	-38.2%	-37.0%
ROE %	8.5%	8.0%	-39.1%	3.9%	-0.1%	-7.4%	2.3%	-18.0%	-	-18.7%	-29.2%	-19.1%	-28.6%
ROCE %	-	-225.8%	-10.7%	3.6%	-1.6%	-7.4%	-6.6%	-12.9%	-	-11.0%	-14.3%	-12.0%	-25.2%

Shareholding Pattern

Insiders

3.62%

Institutions

102.30%

Public Float

106.15%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	15.48%	9.09M	$1.34B
2	Janus Henderson Group PLC	9.11%	5.35M	$790.20M
3	Primecap Management Company	5.74%	3.37M	$497.99M
4	Vanguard Portfolio Management LLC	5.46%	3.21M	$474.02M
5	Vanguard Capital Management LLC	4.27%	2.51M	$370.66M
6	State Street Corporation	3.72%	2.18M	$322.47M
7	Ameriprise Financial, Inc.	2.74%	1.61M	$237.98M
8	Citadel Advisors Llc	2.46%	1.45M	$213.78M
9	Alliancebernstein L.P.	2.38%	1.40M	$206.48M
10	Holocene Advisors, LP	2.36%	1.38M	$204.44M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GKOS

Google News Wed, 08 Jul 2026

GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOdXdtOWtrekdQbnVRTGZoVUVxQkIwWTlYRENKSEpTSW9Mdmg2OThlZnlidmJLMkQxM0JUUEUtRVpVOEdSb0V3OW5hWHpRN05jUHRwWUp5NUs1clhlZWxNNVNoSFZOdzNBejdKd1A0WGlXYTYwTTBIMTJqOUU0elFScXNiX1JIbkE5QUVYcV…

Google News hu, 09 Jul 2026

Insider Sale: SVP & CHIEF FINANCIAL OFFICER of $GKOS Sells 10,000 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQWnhGSFNnYkNkcTlUT29Tb2djOE15a3RILUIyZGxZRl9fSkdhQ1BQWUI5VkRnQ0RpQ0ZuNzhzckVmbHU1RkRiUmVraWh1QndRTGVIQlNYT1BwSlJjWU5wM2JRMTVXMEpuNEFNeUxDUTZRdGwtVExQVVR1MkNkbXlmc0MwZVYxOHRyRUxJRE…

Google News Wed, 08 Jul 2026

Glaukos sets July 29 call for Q2 results after market close - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOX3I4NDlsTTFpX2VzMzZ4aVVzcmZrenNSd1JTSGNUX0tCczBzT0otRmstUl95emtuWTg5Z3RVS0dUMjE4dXM5b2xwNnlSNTlPZFFKWkFNM1JnUzJlWldoLWhTM05FU05aUXNVRzkxVlN4QUtuajZnbzMzT0VlNnAzWS1lSlpJZk9oXy1Zaj…

Google News Mon, 13 Jul 2026

Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio? - RTTNews

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQTkJEUngyaU1MZ0pBS2hqSlI5UE5QNHZQNzIzSkd4LUxlQnQ3VFVuMFA5dFJ5bHhTdGlCWm5KcVAyckJ1ZV8ySnYxODRCeTVYd1lHOU81TW5NTTdmb29HWVV3UHF3LTRoMWNBdVR1c05PN2FWUDl3WFR4MmZGV3RHaHlRRmMyQ0RVc201M1…

Google News Wed, 08 Jul 2026

This Glaucoma Therapy Company Is Keeping An Eye On Profits - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNOVhhd2dVOEllTUx6QUloTDNGQ2FhdzBWejRxanFGWHNSZWFIYXNNNGhUWV95RGY5RUw4UFBhVVlUeUtFam5zQ3Awamc0UGZXalE5SFkyYkxwNFU4MHoxMXZjUTZlUUZmeVc2SFdEU1NhdVp6SXY1ckN5bU1pRjdZUGF0MGU0VTV2cjBZ?o…

Google News hu, 09 Jul 2026

Citi Sticks to Its Buy Rating for Glaukos (GKOS) - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNcGsyX3JHaFJyeGNIYzlWTUJMRW9zdWRrZm92SzNtR2F3N1RCd014a09zc2E5ZF9iWm92TVJRbjNEbWRwa2I0dWZIbHgwUm1KRW5MTkxPbnF1ZXNqa0t2dTczaDhXMmtiOUotVGdNTy1DTnJxTF9JclZwVkJ6MkN3QzExTlFWNVhQc2NzV1…

GKOS — Frequently Asked Questions

What is the current share price of Glaukos Corporation (GKOS)?

As of 2026-07-14 21:23 PDT, Glaukos Corporation (GKOS) trades at $152.45 on NYSE. Its 52-week range is $74.67 to $155.07.

What is the market capitalisation of GKOS?

Glaukos Corporation (GKOS) has a market capitalisation of $8.95B on NYSE.

What is the P/E ratio of GKOS?

GKOS trades at a trailing price-to-earnings (P/E) ratio of -46.20. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 11.03.

What is the return on equity (ROE) of GKOS?

GKOS has a return on equity (ROE) of -26.39%. Its return on capital employed (ROCE) is -25.20%.

Is GKOS a good stock to buy?

This page provides a data-driven analysis of Glaukos Corporation (GKOS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Glaukos Corporation GKOS R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally? - Yahoo Finance

Insider Sale: SVP & CHIEF FINANCIAL OFFICER of $GKOS Sells 10,000 Shares - Quiver Quantitative

Glaukos sets July 29 call for Q2 results after market close - Stock Titan

Returns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio? - RTTNews

This Glaucoma Therapy Company Is Keeping An Eye On Profits - Investor's Business Daily

Citi Sticks to Its Buy Rating for Glaukos (GKOS) - The Globe and Mail

GKOS — Frequently Asked Questions

What is the current share price of Glaukos Corporation (GKOS)?

What is the market capitalisation of GKOS?

What is the P/E ratio of GKOS?

What is the return on equity (ROE) of GKOS?

Is GKOS a good stock to buy?

Explore More